Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELOSEF '250' is an oral cephalosporin antibiotic containing cephradine 250 mg in capsule form, indicated for bacterial infections. Cephradine is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. This product is a conventional small-molecule antibiotic positioned for oral treatment of susceptible bacterial infections.
Pre-Launch
Pre-launch status indicates early-stage commercial planning with opportunity to build launch infrastructure and establish market positioning in the generic/established antibiotic segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on VELOSEF '250' at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.